Eric Karas Buys Shares of SPRY $SPRY
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Eric Karas, Chief Commercial Officer at ARS Pharmaceuticals, Inc. ($SPRY), bought 25,000 shares at an average price of $1.50, for a total transaction of $37,500. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
ARS Pharmaceuticals, Inc. Stock Up 65.7%
Shares of ARS Pharmaceuticals, Inc. ($SPRY) traded around $9.76 on Saturday, up 65.7% for the day.
ARS Pharmaceuticals, Inc. Earnings
Analysts Set New Price Targets
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Get ARS Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SPRY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.